Given the improvements in the national health insurance policy for TTP, i.e., coverage of ADAMTS13 activity and inhibitor assays and removal of the upper frequency limit of plasma exchange treatments, the original guidelines were partially revised and published as the “Diagnostic and Treatment Guidelines for TTP 2020” (Japanese version only). Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.